Wide Ranks

CLDI

Calidi Biotherapeutics, Inc.

2.14

Top Statistics
Market Cap 37 M Forward PE -2.38 Revenue Growth 0.00 %
Current Ratio 0.12 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -0.8550 Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 836000 Total Cash Per Share 0.1030 Total Debt 8 M
Total Debt To Equity Current Ratio 0.12 Book Value Per Share -2.32
All Measures
Short Ratio 88.00 % Message Board Id finmb_572193913 Fax 858 794 9605
Shares Short Prior Month 161034 City San Diego Uuid 9a7984e0-6061-3b4d-bf45-163ad44f97ec
Previous Close 1.93 First Trade Date Epoch Utc 1 B Book Value -2.32
Beta 0.5750 Total Debt 8 M Volume 1 M
Last Split Date 1 B Fifty Two Week Low 0.7300 Total Cash Per Share 0.1030
Shares Short Previous Month Date 1 B Target Median Price 6.25 Max Age 86400
Recommendation Mean 1.00 Sand P52 Week Change 0.3133 Target Mean Price 6.25
Net Income To Common -24916000 Ask 2.13 Short Percent Of Float 0.0577
Implied Shares Outstanding 17 M Last Fiscal Year End 1 B Trailing Peg Ratio None
Average Daily Volume10 Day 2 M Average Volume10days 2 M Total Cash 836000
Next Fiscal Year End 1 B Held Percent Insiders 0.1816 Trailing PE 0.0000
Date Short Interest 1 B Most Recent Quarter 1 B Regular Market Previous Close 1.93
Target Low Price 2.50 Gmt Off Set Milliseconds -18000000 Fifty Day Average 1.43
Open 2.14 Free Cashflow -47570124 State CA
Dividend Yield 0.00 % Return On Assets -2.22 Time Zone Short Name EST
Trailing Eps -1.04 Day Low 1.94 Address1 4475 Executive Drive
Shares Outstanding 17 M Price Hint 4 Target High Price 10.00
Website https://www.calidibio.com 52 Week Change -0.8981 Average Volume 1 M
Forward Eps -0.9000 Recommendation Key strong_buy Compensation As Of Epoch Date 1 B
Quick Ratio 7.80 % Last Split Factor 1:10 Regular Market Day High 2.30
Is_sp_500 False Profit Margins 0.00 % Fifty Two Week High 26.30
Day High 2.30 Shares Short 585626 Regular Market Open 2.14
Industry Key biotechnology Bid 2.13 Earnings Growth 0.00 %
Revenue Growth 0.00 % Shares Percent Shares Out 0.0501 Operating Cashflow -28028000
Currency USD Time Zone Full Name America/New_York Market Cap 37 M
Is_nasdaq_100 False Zip 92121 Quote Type EQUITY
Industry Biotechnology Long Name Calidi Biotherapeutics, Inc. Regular Market Day Low 1.94
Held Percent Institutions 0.0271 Current Price 2.14 Address2 Suite 200
Enterprise To Ebitda -0.8550 Financial Currency USD Current Ratio 0.12
Industry Disp Biotechnology Number Of Analyst Opinions 2 Country United States
Float Shares 5 M Two Hundred Day Average 2.66 Enterprise Value 24 M
Forward PE -2.38 Regular Market Volume 1 M Ebitda -29177000
Exchange ASE
Go to Yahoo Finance Go to Seeking Alpha 
Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States.

Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors.

The company offers NeuroNova platform and SuperNova platform.

The company is headquartered in San Diego, California.